Hony offloads 11% stake in CSPC

The private equity firm raises HK$4.095 billion from the sale of 650 million secondary shares in the Chinese pharmaceuticals group.

Private equity firm Hony Capital divested an 11% stake in CSPC Pharmaceutical after Thursday's close in Hong Kong, raising HK$4.095 billion US$528 million from the sale of 650 million secondary shares.

Under the lead management of Goldman Sachs, Morgan Stanley and UBS, the group priced the accelerated block at HK$6.30 per share. This represented the very bottom end of a HK$6.30 to HK$6.45 range and an 8.3% discount to the stock's HK$6.87 close.

The order book was said to have closed just over two times covered, with participation from roughly 100 accounts. In terms of allocations, the top 10 investors...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222